Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Free Cash Flow (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Free Cash Flow for 4 consecutive years, with -$14.1 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow rose 54.98% to -$14.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$104.1 million through Dec 2025, down 29.64% year-over-year, with the annual reading at -$104.1 million for FY2025, 29.64% down from the prior year.
  • Free Cash Flow for Q4 2025 was -$14.1 million at Day One Biopharmaceuticals, down from -$6.1 million in the prior quarter.
  • The five-year high for Free Cash Flow was $50.0 million in Q3 2024, with the low at -$59.3 million in Q1 2025.
  • Average Free Cash Flow over 4 years is -$27.6 million, with a median of -$30.6 million recorded in 2022.
  • The sharpest move saw Free Cash Flow soared 234.83% in 2024, then crashed 112.24% in 2025.
  • Over 4 years, Free Cash Flow stood at -$35.3 million in 2022, then dropped by 16.56% to -$41.2 million in 2023, then rose by 23.64% to -$31.4 million in 2024, then skyrocketed by 54.98% to -$14.1 million in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at -$14.1 million, -$6.1 million, and -$24.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.